Saira Ramasastry net worth and biography

Saira Ramasastry Biography and Net Worth

Director of Mirum Pharmaceuticals

Saira Ramasastry has served as a member of our board of directors since June 2022. Ms. Ramasastry is the managing partner of Life Sciences Advisory, LLC, an independent firm that she founded to provide strategic advice and business development solutions for life science companies. Prior to founding Life Sciences Advisory, Ms. Ramasastry spent 10 years as an investment banker with Merrill Lynch & Company, where she helped establish the biotechnology practice and advised on mergers and acquisitions, and strategic and capital markets transactions. Previously, she served as a financial analyst in mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry currently serves on the board of directors for DayOne Biopharmaceuticals, Inc., Vir Biotechnology Inc., Akouos, Inc., and Glenmark Pharmaceuticals Ltd. She is also a health innovator fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. Ms. Ramasastry holds a B.A. in economics and an M.S. in management science and engineering with honors and distinction from Stanford University, as well as an M. Phil. in management studies from the University of Cambridge.

What is Saira Ramasastry's net worth?: The estimated net worth of Saira Ramasastry is at least $1.87 million as of June 21st, 2024. Ms. Ramasastry owns 40,485 shares of Mirum Pharmaceuticals stock worth more than $1,873,646 as of March 27th. This net worth evaluation does not reflect any other assets that Ms. Ramasastry may own. Learn More about Saira Ramasastry's net worth.
How do I contact Saira Ramasastry?: The corporate mailing address for Ms. Ramasastry and other Mirum Pharmaceuticals executives is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. Mirum Pharmaceuticals can also be reached via phone at (650) 667-4085 and via email at ir@mirumpharma.com. Learn More on Saira Ramasastry's contact information.
Has Saira Ramasastry been buying or selling shares of Mirum Pharmaceuticals?: Saira Ramasastry has not been actively trading shares of Mirum Pharmaceuticals in the last ninety days. Most recently, Saira Ramasastry sold 5,000 shares of the business's stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $25.68, for a transaction totalling $128,400.00. Learn More on Saira Ramasastry's trading history.
Who are Mirum Pharmaceuticals' active insiders?: Mirum Pharmaceuticals' insider roster includes Eric Bjerkholt (CFO), Ian Clements (CFO), James Flynn (Major Shareholder), Michael Grey (Chairman of the Board), Patrick Heron (Director), Jolanda Howe (SVP), Lara Longpre (Chief Development Officer), Christopher Peetz (Co-Founder, CEO and Director), Joanne Quan (Chief Medical Officer), Peter Radovich (President & Chief Operating Officer), Saira Ramasastry (Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Mirum Pharmaceuticals?: During the last twelve months, Mirum Pharmaceuticals insiders bought shares 4 times. They purchased a total of 3,680 shares worth more than $124,300.35. During the last twelve months, insiders at the sold shares 17 times. They sold a total of 172,113 shares worth more than $7,304,987.14. The most recent insider tranaction occured on March, 17th when SVP Jolanda Howe sold 57,606 shares worth more than $2,554,826.10. Insiders at Mirum Pharmaceuticals own 22.9% of the company. Learn More about insider trades at Mirum Pharmaceuticals.
Information on this page was last updated on 3/17/2025.

Saira Ramasastry Insider Trading History at Mirum Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/5/2024	Sell	5,000	$25.68	$128,400.00

Saira Ramasastry Buying and Selling Activity at Mirum Pharmaceuticals

Mirum Pharmaceuticals Company Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Today's Range

Now: $46.28

$45.83

$47.20

50 Day Range

MA: $48.02

$43.01

$53.16

2 Week Range

Now: $46.28

$23.14

$54.23

Volume

393,047 shs

Average Volume

509,454 shs

Market Capitalization

$2.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04